TriLink BioTechnologies, a leader in oligonucleotide and mRNA synthesis for research, diagnostics and therapeutics, announced today that Brian Neel has joined the company as chief operating officer. In that role, Neel will be responsible for TriLink BioTechnologies operations including site leadership, facilities, sourcing and manufacturing.
Neel brings more than 15 years of experience in the life science and diagnostic industries to TriLink BioTechnologies. He has worked at Synthetic Genomics, GenMark Diagnostics and Life Technologies (now Thermo Fisher Scientific). With a degree in microbiology, Neel specializes in developing and optimizing manufacturing sites and in operations management.
Carl Hull, CEO of Maravai LifeSciences, commented, "We are pleased that Neel is joining our team, as we work to expand TriLink Biotechnologies. His experience with building and operating GMP manufacturing facilities will be invaluable."
Founded in 1996, TriLink BioTechnologies is a global leader in the synthesis of high-quality nucleic acid and mRNA products for research, diagnostics, therapeutics and OEM customers. TriLink BioTechnologies’ products are instrumental in the discovery and development processes in gene and oligonucleotide therapy, nucleoside chemotherapy and diagnostics. The company is ISO 9001 certified and is compliant with ICH Q7, 21 CFR 210 and 21 CFR 820. TriLink BioTechnologies is headquartered in San Diego, Calif., where it also maintains its manufacturing facilities. The company was acquired by Maravai LifeSciences in 2016.
David Weber, Chief Commercial Officer